In serum, insulin-like growth factors (IGFs) are primarily present as a approximately 150 kDa ternary protein complex, which consists of IGFs, IGF binding protein-3 (IGFBP-3), and acid-labile subunit (ALS). Like IGF-I and IGFBP-3, serum levels of ALS depend on growth hormone (GH). To date, the diagnostic relevance of ALS in adult GH deficiency (GHD) has remained uncertain. To clarify the clinical utility of ALS measurement in adults, we measured serum ALS levels in patients with adult GHD or acromegaly. We also measured the levels of serum IGF-I and IGFBP-3 in these patients to compare the utility of ALS with IGF-I and IGFBP-3 as a marker of GH secretion. Serum ALS was measured by radioimmunoassay (RIA) kit, and serum IGF-I and IGFBP-3 were measured by immunoradiometric assay (IRMA) kits in 56 patients with adult GHD (adult-onset (AO)/child-onset (CO), 13/43) and 43 patients with acromegaly. Serum ALS levels were less than 5th percentile in 40 of 56 (71%) patients with adult GHD (32/43 (74%) for CO and 8/13 (62%) for AO), and more than 95th percentile in 38 of 43 (88%) patients with acromegaly, respectively. Serum IGF-I levels were less than -1.96 SD in 43 of 56 (77%) patients with adult GHD (35/43 (81%) for CO and 8/13 (62%) for AO) and more than +1.96 SD in 42 of 43 (98%) patients with acromegaly, respectively. Serum IGFBP-3 levels were less than -1.96 SD in 51 of 56 (91%) patients with adult GHD (42/43 (98%) for CO and 9/13 (69%) for AO) and more than +1.96 SD in 31 of 43 (72%) patients with acromegaly, respectively. These data suggested that measurement of ALS offers no advantage over measurements of serum IGF-I and IGFBP-3. Furthermore, our results indicate that serum IGFBP-3 is the most suitable marker of GH secretion for adult GHD, especially CO, while IGF-I may be the most useful in acromegaly.

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.49.379DOI Listing

Publication Analysis

Top Keywords

adult ghd
24
igf-i igfbp-3
20
patients adult
20
serum igf-i
16
patients acromegaly
16
serum als
12
acromegaly serum
12
serum
11
patients
10
als
9

Similar Publications

Impact of non-weight-dependent low-dose somatropin on bone accrual in childhood-onset GH deficient in the transition: an 18-month randomized controlled trial.

J Pediatr (Rio J)

December 2024

Faculdade de Medicina da Universidade de São Paulo (FMUSP), Instituto da Criança, Unidade de Endocrinologia Pediátrica, São Paulo, São Paulo, Brazil.

Objective: Discontinuation of growth hormone therapy (rhGH) upon completion of linear growth may adversely affect bone mineral density and content (BMD/BMC) in adolescents with childhood-onset GH deficiency (CO-GHD) and predisposition to osteoporosis. Although the benefits of weight-dependent somatropin high doses over bone gain are established, little is known about fixed low doses. We analyzed the impact of non-weight-based low-dose somatropin on bone accrual during the transition among CO-DGH patients, treated since childhood.

View Article and Find Full Text PDF

Objective: This study aimed to determine the response to growth hormone (GH) therapy of patients with growth hormone deficiency (GHD), idiopathic short stature (ISS), and small for gestational age (SGA).

Materials And Methods: The data of the 202 children who received GH treatment were analyzed retrospectively. Laboratory parameters, puberty stages, annual growth rates, body mass index (BMI), GH side effects, target height (TH), estimated adult height (EAH), and bone age (BA) were obtained during the GH treatment period.

View Article and Find Full Text PDF

Purpose: Long-term studies are needed to investigate the safety of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD) in routine practice. The objective of this study was to evaluate the safety and effectiveness of biosimilar rhGH (somatropin; Omnitrope) in adults with GHD.

Methods: PAtients TReated with Omnitrope (PATRO) Adults was a post-marketing surveillance study conducted across Europe.

View Article and Find Full Text PDF
Article Synopsis
  • * Most children (64.1%) were diagnosed with idiopathic short stature, and a significant number (58.9%) of those treated were male, with an average initial diagnosis age of 6.9 years.
  • * The findings emphasize the necessity for consistent monitoring of growth in all children, especially females, those from low socio-economic backgrounds, and minority groups, to ensure effective treatment options and improved adult height outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • - Adulthood growth hormone deficiency (GHD) leads to negative changes in body composition, exercise capacity, cardiovascular function, and metabolism, impacting overall quality of life.
  • - Long-term treatment with recombinant human GH has been shown to improve fracture risk, lipid metabolism, body composition, and quality of life, with minimal side effects at recommended dosages.
  • - Endocrinologists play a crucial role in selecting appropriate candidates for GH therapy, considering their clinical profile, quality of life, and commitment to treatment to ensure effective and safe outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!